Confirmation of reported aspirin use in community studies

Utility of serum thromboxane B2 measurement

Nicole D Zantek, Russell V Luepker, Sue Duval, Karen Miller, Niki Oldenburg, Alan T Hirsch

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

Original languageEnglish (US)
Pages (from-to)385-392
Number of pages8
JournalClinical and Applied Thrombosis/Hemostasis
Volume20
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Thromboxane B2
Aspirin
Serum
Alligators and Crocodiles
Thromboxanes
Compliance
Anti-Inflammatory Agents
Cardiovascular Diseases
Sensitivity and Specificity
Health
Pharmaceutical Preparations
Population

Keywords

  • NSAID
  • aspirin
  • cardiovascular prevention
  • compliance
  • nonsteroidal anti-inflammatory drug

Cite this

Confirmation of reported aspirin use in community studies : Utility of serum thromboxane B2 measurement. / Zantek, Nicole D; Luepker, Russell V; Duval, Sue; Miller, Karen; Oldenburg, Niki; Hirsch, Alan T.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 20, No. 4, 01.01.2014, p. 385-392.

Research output: Contribution to journalArticle

@article{6860350ab01943449dd9688667650651,
title = "Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement",
abstract = "Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1{\%}) and specificity (91.1{\%}) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.",
keywords = "NSAID, aspirin, cardiovascular prevention, compliance, nonsteroidal anti-inflammatory drug",
author = "Zantek, {Nicole D} and Luepker, {Russell V} and Sue Duval and Karen Miller and Niki Oldenburg and Hirsch, {Alan T}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1076029613486537",
language = "English (US)",
volume = "20",
pages = "385--392",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Confirmation of reported aspirin use in community studies

T2 - Utility of serum thromboxane B2 measurement

AU - Zantek, Nicole D

AU - Luepker, Russell V

AU - Duval, Sue

AU - Miller, Karen

AU - Oldenburg, Niki

AU - Hirsch, Alan T

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

AB - Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

KW - NSAID

KW - aspirin

KW - cardiovascular prevention

KW - compliance

KW - nonsteroidal anti-inflammatory drug

UR - http://www.scopus.com/inward/record.url?scp=84899028752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899028752&partnerID=8YFLogxK

U2 - 10.1177/1076029613486537

DO - 10.1177/1076029613486537

M3 - Article

VL - 20

SP - 385

EP - 392

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 4

ER -